Graduate Training in Radiopharmaceutical Chemistry

放射性药物化学研究生培训

• 批准号: 7232221
• 负责人: SILVIA S. JURISSON
• 金额: $ 13.8万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7232221
• 关键词: Chemistry; Radiopharmaceuticals; Training

DESCRIPTION (provided by applicant): Advances in radiopharmaceutical and radiotracer chemistry have made an enormous impact on the practice of health care. Yet, the shortage of PhD chemists in this multidisciplinary area persists even though it was documented in a National Research Council report in 1988. This shortage places a sense of urgency on developing mechanisms, which accomplish the dual goals of providing a solid graduate training in modern synthetic chemistry and radiochemistry while at the same time providing students with research experience and exposure in the multidisciplinary area of radiopharmaceutical and radiotracer chemistry. This T32 Application in Radiopharmaceutical and Radiotracer Chemistry is a multi-institutional graduate student training program. The overall plan of the proposal is to build a firm foundation in chemical principles, coupled with a dissertation that emanates from research conducted with individuals at three highly respected institutions (University of Missouri-Columbia (MU-Columbia), Brookhaven National Laboratory (BNL), and the National Cancer Institute (NCI)). We expect the selected T32 Fellows to be more adventurous and self- motivated than a typical graduate student in order to accomplish the objectives we describe. The value- added approach of this proposal is that the T32 Fellows will learn not only fundamental techniques at three different sites, but will also be trained in recognizing the "big questions" currently facing biomedical science and how molecular imaging/therapy can be used. They will gain a more comprehensive view of the field that generally only comes after the combined experiences of graduate, postdoctoral, and job training. We firmly believe that the cross-fertilization inherent in this program will provide the T32 Fellows a mechanism to experience the scientific world they are entering before they conduct postgraduate training. Their postdoctoral training will thereby be much more focused and much more productive. Ten PhD candidates will matriculate over an initial five year period. We expect the Fellows will have successfully (1) fullfilled the PhD requirements at MU-Columbia, (2) completed multidisciplinary research, and (3) experienced an extended internship at either BNL or the NCI followed by a shorter internship at the second site. Graduates of this program will be future participants in the field by completing this program; however, we aspire for them to become the future leaders in the field, teaching our future generations.

描述（由申请人提供）： 放射性药物和放射性示踪剂化学的进步对医疗保健实践产生了巨大影响。然而，尽管国家研究委员会 1988 年的报告中记录了这一情况，但这一多学科领域化学博士的短缺仍然存在。这种短缺给制定机制带来了紧迫感，这些机制实现了双重目标：提供现代合成化学和放射化学方面扎实的研究生培训，同时为学生提供放射性药物和放射性示踪剂化学多学科领域的研究经验和接触。此 T32 在放射性药物和放射性示踪剂化学中的应用是一个多机构研究生培训项目。该提案的总体计划是在化学原理方面打下坚实的基础，并附上由三个备受尊敬的机构（密苏里哥伦比亚大学 (MU-Columbia)、布鲁克海文国家实验室 (BNL) 和国家癌症研究所 (NCI)）的个人进行的研究得出的论文。我们希望选定的 T32 研究员比典型的研究生更具冒险精神和自我激励，以实现我们描述的目标。该提案的增值方法是，T32 研究员不仅将在三个不同地点学习基本技术，还将接受培训，了解生物医学科学目前面临的“大问题”以及如何使用分子成像/治疗。他们将对这个领域有更全面的了解，而这通常只有在研究生、博士后和工作培训的综合经验之后才能实现。我们坚信，该计划固有的交叉融合将为 T32 研究员提供一种机制，让他们在进行研究生培训之前体验他们即将进入的科学世界。因此，他们的博士后培训将更加集中、更加富有成效。十名博士候选人将在最初的五年内入学。我们预计研究员将成功 (1) 满足 MU-Columbia 的博士学位要求，(2) 完成多学科研究，以及 (3) 在 BNL 或 NCI 进行长期实习，然后在第二个地点进行较短的实习。该项目的毕业生将通过完成该项目成为该领域未来的参与者；然而，我们渴望他们成为该领域未来的领导者，教育我们的子孙后代。